MTOR and hepatocellular carcinoma: In addition, the silencing of some CPSFs has also been determined to inhibit cancer progression by inhibiting the PI3K/AKT/mTOR pathway, such as the CPSF3-PI3K/Akt/GSK-3β in HCC [17], CPSF4-PI3K/AKT in LUAD [10], and CPSF7-PTEN/AKT in HCC [12].